First Tracks Biotherapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Marine Godin. I am working in the healthcare investment banking team here in London, and it is my pleasure to now introduce Dan Faga, CEO of First Tracks Biotherapeutics.
Well, good afternoon, everyone. Appreciate the Jefferies banking team for the invitation to present here at the conference. These are our forward-looking statements. First Tracks Bio, we are still technically a young company. We were launched via a spin-off from our predecessor in April of this year, and we are leveraged against a very, I think, accepted platform on potent antibody discovery and early-stage development. What we were able to do with First Tracks six months ago was spin off an entity with a research organization engine from the prior company, as well as three clinical-stage therapeutics. One is ANB033. We will spend most of this presentation going through this program in detail, the mechanism of action, and the development plan. What I will start with is we recently announced statistically significant and compelling results, highly compelling results in a celiac trial in a gluten challenge frame.
I will go through that in detail, but we also have a second trial in celiac ongoing. It is a healing study that will read out in the first quarter of next year, as well as a second trial in eosinophilic esophagitis that will read out in the third quarter of next year. Our other two programs are rosnilimab, which is a PD-1 depleter, and ANB101, which is a BDCA2 depleter. A couple notes on the BDCA2. We do have a differentiated profile relative to competitors, namely a large cap with two phase IIIs reading out in SLE and one in CLE in the beginning of next year. The PD profile is differentiated both on half-life of the antibody as well as the depletion profile targeting the BDCA2 on plasmacytoid dendritic cells. I am not going to spend a lot of time on that program in this presentation.
We are committing to the presentation of our phase I-A clinical results next year, and we will announce, following the clinical readouts from the competitor, we will announce our plans forward at that time at some point next year. Now on to ANB033. I think mechanistically, what we are attempting to do here is target and block the CD122 beta subunit, which is presenting in a receptor complex on various immune cells in the setting of disease. You could see in the picture on the slide on the right is a dimeric receptor complex, which we see observed on NK cells as well as, importantly, CD8 T cells. CD122 also presents in a trimeric receptor complex, which we observe in an activated state on CD4 cells.
There are other types of cells that we see in the presence of disease that are relevant for where we are developing the drug. Intraepithelial lymphocytes generally present with a CD8 phenotype in that dimeric receptor, and then ILC2s in the presence of EoE we see in the trimeric receptor. Our program, ANB033, potently blocks the CD122 component of the dimeric or trimeric receptors. What we are doing mechanistically is we are blocking both IL-2 and IL-15 signaling pathways that are important to allow the proliferation and survival of the various CD4 and CD8 T cells in disease. The other component of this with ANB033 is there are various competitors in the profile. We have a highly potent antagonist being driven by a high-affinity antagonist in this therapy. I will show you some slides where we think we see differentiation there relative to other folks in the space.
Where we are in terms of development path, last year we finished or initiated and completed a phase I-A trial in healthy volunteers. There are about 80 patients that were treated with active drug, both in IV and subcutaneous format. We demonstrated up to a three-week half-life with the subcutaneous administration, full receptor occupancy, and I think importantly, when you step back from this trial, a safe and tolerable drug overall. We also saw important PD effects in the plasma of the healthy volunteers. What we are presenting here on the right-hand side of the page are the impact on both CD8 T cells in the top and NK cells in the bottom. We are showing the CD122 expressing TEMRA T cells, as well as the CD122 expressing NK cells. We can see with the NK cells, these cells are highly dependent on IL-15 for survival.
I mentioned earlier that we are blocking the signaling of both. For the NK cells, the CD122 representing NK cells, a 98% elimination of these cells from just the initial subcutaneous dosing, i.e., the lowest dose in the SAD component of the healthy volunteers. You cannot do much better than that. Then with the CD8 T cells, a 74% reduction with that initial subcutaneous starting dose. We dosed higher. We did not see any limiting toxicity through the course of the phase I-A trial. We also performed the MAD components of this. Then lastly, we saw a long-term PD effect. The NK cells, we had presented publicly. We saw a multi-month, at least three-month reduction of those NK cells before we returned to baseline off the initial lower subcutaneous starting dose.
Before we describe and get into the trial results in celiac disease, a little bit about the mechanism of action of ANB033 as it applies to celiac disease biology. There are two pathways we like to describe on what is happening in celiac disease. The first is from the initiation, a patient's response to gluten and the downstream byproduct gliadin that gets picked up by APCs with patients with celiac disease and then presented to CD4 cells that initiate an activation cycle. What is known in this disease is within an hour of CD4 activation, i.e., an hour from gluten exposure, you see a rapid uptake of IL-2 that is also associated with a significant increase in interferon-gamma. The interferon-gamma is one of the initiators of the IL-15 receptor presentation in epithelial cells.
That is the beginning of initiation of then the second immune pathway that is initiating celiac disease that compounds both the symptomatic response that initiates with CD4 cells and then epithelial barrier destruction that you see from IL-15 presentation, a recruitment of IELs, which then perpetuate itself with further downstream tissue damage on the epithelial layer. Both of these pathways work together in the context of this disease. What we are doing, as I mentioned earlier with the CD122 antagonists, is we are blocking both IL-15 signaling, which is really important in terms of decreasing the proliferation and the survival of the IELs, which express with the CD8 phenotype, as well as blocking IL-2 signaling, which prevents the initiation or activation of the CD4 cells, which are linked to acute symptoms in this disease.
It is a dual mechanism in terms of blocking the CD122 presentation on the dimeric form and the trimeric form of the various T cells in this disease. Last year, post the phase I-A results, we initiated two different cohorts within celiac disease. A prevention cohort one, we were looking at patients on presentation at a VHCD of greater than two. VHCD is villus height to crypt depth ratio. It is a way to measure the mucosal or the inflammatory injury in the intestine of patients with disease. Greater than two is considered moderate or mild disease. For these patients in the first cohort, we gave a baseline subcutaneous dose at baseline, day 0, week two, and week four. Then we administered a 14-day gluten challenge of 6 grams of gluten a day. That is the equivalent of a daily dose of about two to three slices of bread.
We did that continuously for 14 days and then did a biopsy at the end of the sixth week. The second cohort in the study is treating the patients who did not qualify for that gluten challenge. The patients who enrolled in the second cohort, they had a VHCD initially less than 2.0. We later modified that trial to look at patients less than 2.5 on VHCD. These are patients with severe or moderate to severe mucosal injury at baseline. Similar to cohort one, we dosed patients at week 0, week two, and week four. However, in this study, we will be looking at the results at week 12 via biopsy. There is no gluten challenge in this study. We are looking eight weeks from that last dose to see the impact that we have had on drug versus placebo on healing of VHCD as the primary analysis.
We have a lot of confidence based on what I discussed earlier in the phase I-A results that we do have a PD effect with a long-term PD effect with a IC90 concentration in tissue based on the tox studies in the phase I-A through that 12th week. Both of these cohorts were initiated at the same time. We read out, and I will walk through the data from cohort one last month. Cohort two has completed enrollment, and we will have those study results in the first quarter of 2027. Here are the baseline characteristics from the cohort one gluten challenge results. I think there is not a lot to see in terms of the differentiation between the number of patients we enrolled, 15 patients in placebo, 17 on drug, so more or less a one-to-one randomization.
I think importantly here, and I think consistent with others in the space, we see a baseline VHCD that we enrolled in the trial, again, greater than 2.0 in terms of the inclusion criteria. The baseline here is about 2.75 across both arms. The results. We hit statistical significance on the delta on VHCD. The significance was so far best in disease of 0.49 delta versus placebo. Importantly here, what you can see in the control arm was we saw a decrease of 0.66 on VHCD for the patients who were on placebo. Only 14 days with 6 grams a day, we saw a very significant deterioration for patients in the control of 0.66. What you could then say was we administered an intense gluten challenge. We know this worked. Beyond just the delta of the drug working relative to the control, it's important to then observe we were preventative of significant deterioration.
There's a consensus emerging across KOLs, and there's different answers out there, but general consensus of a minus 0.25 being clinically meaningful. We were lower than that threshold of a decrease of 0.17 on drug. So preventative of damage on drug. You then couple that with one of the important biomarkers. I talked earlier about IELs, intraepithelial lymphocytes, that present themselves and help drive the deterioration of the lining of the gut. We not only showed a statistically significant difference versus the controls, and this is shown on the left, we actually decreased from baseline the number of IELs even in the presence of the gluten challenge.
In an intense gluten challenge, this is the first time a company has shown a reduction of IELs in a gluten challenge that was this significant, and that's a pretty radical and important difference. Combined between prevention on VHCD and the IELs, we've shown a robust composite of a histological benefit in this trial. The VCIEL is a composite of both. It's a mathematical equation of both the impact on IELs and VHCD. We hit stats on both the individual components, we hit statistical significance on the combined composite. Then there was the symptomatic impact, and this truly was an upside surprise, and it was to us, even within the company, while the hypothesis was there that by blocking both IL-15 and also IL-2 signaling that we could see a symptom difference, no one has ever seen results like this before presented. A few things happened. Number one, in the context of that 14-day gluten challenge, the patients on drug saw no increase in symptoms throughout the entire 14 days.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
